Anastrozole Tablet, Coated
Product Images NDC 71335-3145

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 71335-3145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structured Formula For Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 01)

FDA Label Image

Structured Formula For Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 02)

This is a table showing disease-free survival over a certain period of time for patients treated with anastrozole and tamoxifen. The data includes the number of patients at risk at various time points. The table represents a comparison of these two treatments in terms of disease-free survival in months. The proportion of patients alive at different time intervals is also shown.*

FDA Label Image

Structured Formula For Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 03)

This is a graph showing disease-free survival in months for patients treated with anastrozole and tamoxifen over a span of 90 months. The number of patients at risk is also provided for each time point. This data can be used to evaluate the effectiveness of the two treatments in prolonging disease-free survival.*

FDA Label Image

Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 04)

This text appears to be a presentation of data related to a medical study comparing the effectiveness of two treatments, anastrozole and tamoxifen, over a time period of up to 120 months. The data includes the number of patients at risk at various time points and mentions improving the clarity of Kaplan-Meier curves by truncating the vertical axis. This information is part of an evaluation of the proportion of event-free patients over time for each treatment group.*

FDA Label Image

Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 05)

This is a evaluation data of a clinical trial comparing two treatments: Anastrozole and Tamoxifen, in terms of time to an event occurring over several months. The number of patients at risk at different time points is provided. The graph representation of the data uses Kaplan-Meier curves, with the vertical axis truncated for clarity.*

FDA Label Image

Structured Formula For Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 06)

This text seems to be a comparison of two treatments (anastrozole and tamoxifen) based on the time to progression (in months). It provides the number of patients at risk for progression at different time points during the study. The information suggests that the proportion of patients not progressing over time is being monitored and compared between the two treatments.*

FDA Label Image

Structured Formula For Anastrozole Tablets (577b7171 5da0 4291 Af07 5e4653ffb3aa 07)

This data seems to show a comparison of time to progression in patients under different treatments (Anastrozole and Tamoxifen) over a period of 40 months. The table displays the number of patients at risk at various time points throughout the study. The information seems to suggest that there was no clear progression pattern observed in the study.*

FDA Label Image

Label (Lbl713353145)

This product is Anastrozole Tablets, USP containing 1 mg each. It is important to keep out of reach of children, store at room temperature in a tight container, and refer to the package insert for detailed dosage instructions.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.